Immunotech Biopharm (HKSE:06978) Net Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06978 Immunotech Biopharm Ltd HKSE:06978
17 GF Score
Price HK$0.39
! 4 Warning Signs
View Full Analysis

What is Immunotech Biopharm Net Margin %?

Immunotech Biopharm HKSE:06978 17 Net Margin % is 0.00% as of Dec. 2025. GuruFocus rates HKSE:06978 with a GF Score™ of 17/100. The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, Immunotech Biopharm ranks worse than 105820% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Immunotech Biopharm's Net Income for the six months ended in Dec. 2025 was HK$-112.33 Mil. Immunotech Biopharm's Revenue for the six months ended in Dec. 2025 was HK$0.00 Mil. Therefore, Immunotech Biopharm's net margin for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Immunotech Biopharm's Net Margin % or its related term are showing as below:


HKSE:06978's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -83.18
* Ranked among companies with meaningful Net Margin % only.

Immunotech Biopharm  (HKSE:06978) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Immunotech Biopharm Net Margin % Related Terms

Immunotech Biopharm Net Margin % Historical Data

* Premium members only.

The historical data trend for Immunotech Biopharm's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunotech Biopharm Net Margin % Chart

Immunotech Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Immunotech Biopharm Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HKSE:06978 vs VRTX, REGN, RVMD: Net Margin % Comparison

For the Biotechnology subindustry, Immunotech Biopharm's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunotech Biopharm Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's Net Margin % distribution charts can be found below:

* The bar in red indicates where Immunotech Biopharm's Net Margin % falls into.


HKSE:06978
17GF Score
Immunotech Biopharm Ltd HKSE:06978
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunotech Biopharm Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Immunotech Biopharm's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-254.954/0
= %

Immunotech Biopharm's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-112.331/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Immunotech Biopharm (HKSE:06978) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Immunotech Biopharm and its competitors. According to the industry distribution chart, Immunotech Biopharm ranks #999999 out of 945 companies in the Biotechnology industry.
Is Immunotech Biopharm's Net Margin % too high?
Immunotech Biopharm's current Net Margin % is 0.00%. Based on the distribution chart, Immunotech Biopharm ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immunotech Biopharm has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Immunotech Biopharm's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immunotech Biopharm ranks #999999 out of 945 companies for Net Margin %. This places Immunotech Biopharm in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Immunotech Biopharm and its competitors. Immunotech Biopharm's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunotech Biopharm stock overvalued right now?
Immunotech Biopharm (HKSE:06978) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Immunotech Biopharm's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Immunotech Biopharm (HKSE:06978), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunotech Biopharm Business Description

Address No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
17GF Score

Get the complete analysis for HKSE:06978

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.39
Price